Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2024 | Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC

Alexander Spira, MD, PhD, FACP, Next Oncology-Virginia VCS, Fairfax, VA, discusses the Phase III MARIPOSA-2 (NCT04988295) trial, which explored the effectiveness of amivantamab in combination with carboplatin-pemetrexed with or without lazertinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who had experienced disease progression on osimertinib. Key findings included significant progression-free survival benefits at 6 and 12 months, improved time-to-treatment discontinuation (TTD), and time to subsequent therapy. Dr Spira also discusses post-progression outcomes, highlighting prolonged frontline therapy duration and improved progression-free survival (PFS) after subsequent therapy in the amivantamab plus chemotherapy arm. The study suggests that chemotherapy may represent a new standard of care for patients after osimertinib progression. This interview took place at the ELCC 2024 meeting in Prague, Czech Republic.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.